CAMM (Chromosomal abnormalities in Multiple Myeloma): Study of chromosomal abnormalities by fluorescent in-situ-hyberdisation (FISH), and quantitative polymerase chain reaction (qPCR) in Multiple Myeloma patients and correlations with treatment outcomes.

This study aims at evaluating the prognostic value of chromosome 13 deletions as well as t(4,14) as detected
by the FISH/qPCR techniques in multiple myeloma patients. The impact of these abnormalities in the context of high-dose therapy (HDT) or conventional therapy will help to identify those patients who would maximally benefit from HDT and those who would be refractory to HDT and might benefit from other therapeutic options.
Furthermore, it would be of great value for determining the prognosis of the disease to study the prognostic factors of myeloma, including -13q and t(4;14), at the time of diagnosis, prior to and after transplantation, and at the time of relapse, with special emphasis on the outcome of patients who underwent HDT.
Moreover, these data might supply valuable guidance regarding identification and cloning of a MM-tumour
suppressor gene.